The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Phage Therapy as an Alternative Treatment Modality for Resistant Staphylococcus aureus Infections
Abstract
The production and use of antibiotics increased significantly after the Second World War due to their effectiveness against bacterial infections. However, bacterial resistance also emerged and has now become an important global issue. Those most in need are typically high-risk and include individuals who experience burns and other wounds, as well as those with pulmonary infections caused by antibiotic-resistant bacteria, such as Pseudomonas aeruginosa, Acinetobacter sp, and Staphylococci. With investment to develop new antibiotics waning, finding and developing alternative therapeutic strategies to tackle this issue is imperative. One option remerging in popularity is bacteriophage (phage) therapy. This review focuses on Staphylococcus aureus and how it has developed resistance to antibiotics. It also discusses the potential of phage therapy in this setting and its appropriateness in high-risk people, such as those with cystic fibrosis, where it typically forms a biofilm.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“while endolysins (LysK, Exebacase) hydrolyze peptidoglycan, synergizing with antibiotics (e.g., vancomycin) to reduce MRSA populations by 90% [294,295].”
From Staphylococcus aureus: A Review of the Pathogenesis and Virulence Mechanisms (2025) · cites this paper as [295]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Magiorakos, A.-P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C. G., Harbarth, S., Hindler, J. F., Kahlmeter, G., Olsson-Liljequist, B., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03570.x · Cited by 14,449
Waves of resistance: Staphylococcus aureus in the antibiotic era
Chambers, H. F., & DeLeo, F. R. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2200 · Cited by 2,718
Howden, B. P., Davies, J. K., Johnson, P. D. R., Stinear, T. P., & Grayson, M. L. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00042-09 · Cited by 962
Penicillin as a Chemotherapeutic Agent
Chain, E., Florey, H. W., Gardner, A. D., Heatley, N. G., Jennings, M. A., Orr-Ewing, J., & Sanders, A. G. (1940) · The Lancet · doi:10.1016/s0140-6736(01)08728-1 · Cited by 603
Inhibition of Daptomycin by Pulmonary Surfactant: In Vitro Modeling and Clinical Impact
Silverman, J. A., Mortin, L. I., VanPraagh, A. D. G., Li, T., & Alder, J. (2005) · The Journal of Infectious Diseases · doi:10.1086/430352 · Cited by 541
Interactions between Bacteriophage, Bacteria, and the Mammalian Immune System
Van Belleghem, J. D., Dąbrowska, K., Vaneechoutte, M., Barr, J. J., & Bollyky, P. L. (2018) · Viruses · doi:10.3390/v11010010 · Cited by 408
Fleming’s penicillin producing strain is not Penicillium chrysogenum but P. rubens
Houbraken, J., Frisvad, J. C., & Samson, R. A. (2011) · IMA Fungus · doi:10.5598/imafungus.2011.02.01.12 · Cited by 262
Kowalski, T. J., Berbari, E. F., & Osmon, D. R. (2005) · Mayo Clinic Proceedings · doi:10.4065/80.9.1201 · Cited by 132 · cited 1×
“Subsequent to penicillin, a new variant called methicillin was introduced in 1961 [77], but resistance quickly established [78] and resulted from the acquisition of mecA [79].”
Background
Research works printed but not linked: 164
- Su, 2019, Genome-based prediction of bacterial antibiotic resistance, J. Clin. Microbiol., 57, e01405, 10.1128/JCM.01405-18 · DOI · Paper page
- Trend, 2017, The potential of phage therapy in cystic fibrosis: Essential human-bacterial-phage interactions and delivery considerations for use in Pseudomonas aeruginosa-infected airways, J. Cyst. Fibros., 16, 663, 10.1016/j.jcf.2017.06.012 · DOI
- Kodong, 2020, The monitoring infectious diseases diffusion through GIS, SciTech Framew., 2, 23
- Pincus, N.B., Reckhow, J.D., Saleem, D., Jammeh, M.L., Datta, S.K., and Myles, I.A. (2015). Strain Specific Phage Treatment for Staphylococcus aureus Infection Is Influenced by Host Immunity and Site of Infection. PLoS ONE, 10. · DOI
- Breederveld, 2019, Phage therapy 2.0: Where do we stand?, Lancet Infect. Dis., 19, 2, 10.1016/S1473-3099(18)30502-4 · doi:10.1016/s1473-3099(18)30502-4
- Fish, R., Kutter, E., Bryan, D., Wheat, G., and Kuhl, S. (2018). Resolving Digital Staphylococcal Osteomyelitis Using Bacteriophage—A Case Report. Antibiotics, 7. · doi:10.3390/antibiotics7040087
- Morozova, 2018, Applications of Bacteriophages in the Treatment of Localized Infections in Humans, Front. Microbiol., 9, 1696, 10.3389/fmicb.2018.01696 · DOI
- Lin, 2020, Safety of bacteriophage therapy in severe Staphylococcus aureus infection, Nat. Microbiol., 5, 465, 10.1038/s41564-019-0634-z · DOI · Paper page
- Oduor, J.M.O., Kadija, E., Nyachieo, A., Mureithi, M.W., and Skurnik, M. (2020). Bioprospecting Staphylococcus Phages with Therapeutic and Bio-Control Potential. Viruses, 12. · DOI
- Kornienko, 2020, Contribution of Podoviridae and Myoviridae bacteriophages to the effectiveness of anti-staphylococcal therapeutic cocktails, Sci. Rep., 10, 18612, 10.1038/s41598-020-75637-x · doi:10.1038/s41598-020-75637-x
- McCallin, 2018, Metagenome analysis of Russian and Georgian Pyophage cocktails and a placebo-controlled safety trial of single phage versus phage cocktail in healthy Staphylococcus aureus carriers, Environ. Microbiol., 20, 3278, 10.1111/1462-2920.14310 · DOI
- Romero-Calle, D., Guimarães Benevides, R., Góes-Neto, A., and Billington, C. (2019). Bacteriophages as Alternatives to Antibiotics in Clinical Care. Antibiotics, 8. · DOI · Paper page
- Kållberg, C., Årdal, C., Salvesen Blix, H., Klein, E., Martinez, E.M., Lindbæk, M., Outterson, K., Røttingen, J.-A., and Laxminarayan, R. (2018). Introduction and geographic availability of new antibiotics approved between 1999 and 2014. PLoS ONE, 13. · DOI
- Esteban, 2013, In vitro susceptibility to antibiotics of staphylococci in biofilms isolated from orthopaedic infections, Int. J. Antimicrob. Agents, 41, 521, 10.1016/j.ijantimicag.2013.02.018 · DOI
- Kreiswirth, 1993, Evidence for a clonal origin of methicillin resistance in Staphylococcus aureus, Science, 259, 227, 10.1126/science.8093647 · DOI · Paper page
- Rad, E.G. (2010). Molecular Epidemiology and Therapeutic Potential of Persian Shallot (Allium ascalonicum L.) in the Management of Methicillin Resistant Staphylococcus Aureus Infection. [Ph.D. Thesis, Universiti Putra Malaysia].
- Dickmann, 2017, Communicating the Risk of MRSA: The Role of Clinical Practice, Regulation and Other Policies in Five European Countries, Front. Public Health, 5, 44, 10.3389/fpubh.2017.00044 · DOI
- Ji, Y. (2007). Methicillin-Resistant Staphylococcus aureus (MRSA) Protocols, Humana Press. · doi:10.1007/978-1-59745-468-1
- Partridge, 2018, Mobile genetic elements associated with antimicrobial resistance, Clin. Microbiol. Rev., 31, e00088-17, 10.1128/CMR.00088-17 · DOI · Paper page
- Seemann, 2010, Complete Genome Sequence of Staphylococcus aureus Strain JKD6008, an ST239 Clone of Methicillin-Resistant Staphylococcus aureus with Intermediate-Level Vancomycin Resistance, J. Bacteriol., 192, 5848, 10.1128/JB.00951-10 · doi:10.1128/jb.00951-10
- Pang, 2020, The Genomic Context for the Evolution and Transmission of Community-Associated Staphylococcus aureus ST59 Through the Food Chain, Front. Microbiol., 11, 422, 10.3389/fmicb.2020.00422 · DOI
- Hallin, 2009, StaphVar-DNA microarray analysis of accessory genome elements of community-acquired methicillin-resistant Staphylococcus aureus, J. Antimicrob. Chemother., 63, 877, 10.1093/jac/dkp089 · DOI
- Toft, 2020, Core genome multi-locus sequence typing as an essential tool in a high-cost livestock-associated meticillin-resistant Staphylococcus aureus CC398 hospital outbreak, J. Hosp. Infect., 104, 574, 10.1016/j.jhin.2019.12.009 · doi:10.1016/j.jhin.2019.12.009
- Balaky, S. (2011). The Effect of Antibiotics on Toxin Gene Expression in PVL-positive Staphylococcus aureus Strains. [Ph.D. Thesis, Durham University].
- Holden, 2004, Complete genomes of two clinical Staphylococcus aureus strains: Evidence for the rapid evolution of virulence and drug resistance, Proc. Natl. Acad. Sci. USA, 101, 9786, 10.1073/pnas.0402521101 · DOI · Paper page
- Ioanas, 2004, Linezolid in VAP by MRSA: A better choice?, Intensive Care Med., 30, 343, 10.1007/s00134-003-2135-y · DOI
- Livermore, 2003, Linezolid in vitro: Mechanism and antibacterial spectrum, J. Antimicrob. Chemother., 51, ii9, 10.1093/jac/dkg249 · DOI · Paper page
- Ito, 2004, Novel Type V Staphylococcal Cassette Chromosome mec Driven by a Novel Cassette Chromosome Recombinase, ccrC, Antimicrob. Agents Chemother., 48, 2637, 10.1128/AAC.48.7.2637-2651.2004 · DOI · Paper page
- Zhang, 2009, Novel Staphylococcal Cassette Chromosome mec Type, Tentatively Designated Type VIII, Harboring Class A mec and Type 4 ccr Gene Complexes in a Canadian Epidemic Strain of Methicillin-Resistant Staphylococcus aureus, Antimicrob. Agents Chemother., 53, 531, 10.1128/AAC.01118-08 · DOI · Paper page
- Lakhundi, 2018, Methicillin-Resistant Staphylococcus aureus: Molecular Characterization, Evolution, and Epidemiology, Clin. Microbiol. Rev., 31, e00020-18, 10.1128/CMR.00020-18 · DOI · Paper page
- Chongtrakool, 2006, Staphylococcal Cassette Chromosome mec (SCCmec) Typing of Methicillin-Resistant Staphylococcus aureus Strains Isolated in 11 Asian Countries: A Proposal for a New Nomenclature for SCCmec Elements, Antimicrob. Agents Chemother., 50, 1001, 10.1128/AAC.50.3.1001-1012.2006 · DOI · Paper page
- Rasmussen, 2010, Future challenges and treatment of Staphylococcus aureus bacteremia with emphasis on MRSA, Future Microbiol., 6, 43, 10.2217/fmb.10.155 · DOI
- Kavanagh, 2018, View point: Gaps in the current guidelines for the prevention of Methicillin-resistant Staphylococcus aureus surgical site infections, Antimicrob. Resist. Infect. Control, 7, 112, 10.1186/s13756-018-0407-0 · doi:10.1186/s13756-018-0407-0
- Brown, 2021, Treatment of methicillin-resistant Staphylococcus aureus (MRSA): Updated guidelines from the UK, JAC-Antimicrob. Resist., 3, dlaa114, 10.1093/jacamr/dlaa114 · DOI · Paper page
- Vonberg, 2011, Worldwide Outbreak Database: The largest collection of nosocomial outbreaks, Infection, 39, 29, 10.1007/s15010-010-0064-6 · doi:10.1007/s15010-010-0064-6
- Rubin, 2018, A Sporadic Four-Year Hospital Outbreak of a ST97-IVa MRSA With Half of the Patients First Identified in the Community, Front. Microbiol., 9, 1494, 10.3389/fmicb.2018.01494 · doi:10.3389/fmicb.2018.01494
- Talan, 2016, Trimethoprim–Sulfamethoxazole versus Placebo for Uncomplicated Skin Abscess, N. Engl. J. Med., 374, 823, 10.1056/NEJMoa1507476 · DOI · Paper page
- Talan, 2018, Subgroup Analysis of Antibiotic Treatment for Skin Abscesses, Ann. Emerg. Med., 71, 21, 10.1016/j.annemergmed.2017.07.483 · DOI
- Nathwani, 2008, Guidelines for UK practice for the diagnosis and management of methicillin-resistant Staphylococcus aureus (MRSA) infections presenting in the community, J. Antimicrob. Chemother., 61, 976, 10.1093/jac/dkn096 · DOI · Paper page
- Tanus, 2014, A Randomized, Double-blind, Comparative Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment 1% Versus Oral Linezolid in the Treatment of Secondarily Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus aureus, Adv. Ski. Wound Care, 27, 548, 10.1097/01.ASW.0000456631.20389.ae · DOI
- Noel, 2008, A Randomized, Double-Blind Trial Comparing Ceftobiprole Medocaril with Vancomycin plus Ceftazidime for the Treatment of Patients with Complicated Skin and Skin-Structure Infections, Clin. Infect. Dis., 46, 647, 10.1086/526527 · DOI · Paper page
- Boucher, 2014, Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin Infection, New Engl. J. Med., 370, 2169, 10.1056/NEJMoa1310480 · DOI · Paper page
- Moran, 2014, Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): A randomised, double-blind, phase 3, non-inferiority trial, Lancet Infect. Dis., 14, 696, 10.1016/S1473-3099(14)70737-6 · DOI · Paper page
- John, 2020, The treatment of resistant staphylococcal infections, F1000Research, 9, 150, 10.12688/f1000research.17718.1 · doi:10.12688/f1000research.17718.1
- Gould, 2009, Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom, J. Antimicrob. Chemother., 63, 849, 10.1093/jac/dkp065 · DOI
- Rubinstein, 2011, Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive Pathogens, Clin. Infect. Dis., 52, 31, 10.1093/cid/ciq031 · DOI · Paper page
- Thitiananpakorn, 2020, Association of mprF mutations with cross-resistance to daptomycin and vancomycin in methicillin-resistant Staphylococcus aureus (MRSA), Sci. Rep., 10, 16107, 10.1038/s41598-020-73108-x · DOI
- Puttagunta, 2015, Extended-Duration Dosing and Distribution of Dalbavancin into Bone and Articular Tissue, Antimicrob. Agents Chemother., 59, 1849, 10.1128/AAC.04550-14 · DOI · Paper page
- Filippone, 2017, The Nephrotoxicity of Vancomycin, Clin. Pharmacol. Ther., 102, 459, 10.1002/cpt.726 · DOI · Paper page
- Liu, 2011, Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children, Clin. Infect. Dis., 52, e18, 10.1093/cid/ciq146 · DOI · Paper page
- Choo, 2016, Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia, Infect. Chemother., 48, 267, 10.3947/ic.2016.48.4.267 · DOI · Paper page
- Demir, 2022, How Safe Is the Use of Intrathecal Vancomycin?, World Neurosurg., 160, e55, 10.1016/j.wneu.2021.12.082 · doi:10.1016/j.wneu.2021.12.082
- Gould, 2012, Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: A report of the Working Party of the British Society for Antimicrobial Chemotherapy, J. Antimicrob. Chemother., 67, 269, 10.1093/jac/dkr450 · DOI · Paper page
- Morrisette, T., Alosaimy, S., Abdul-Mutakabbir, J.C., Kebriaei, R., and Rybak, M.J. (2020). The Evolving Reduction of Vancomycin and Daptomycin Susceptibility in MRSA—Salvaging the Gold Standards with Combination Therapy. Antibiotics, 9. · DOI
- Aslam, 2018, Antibiotic resistance: A rundown of a global crisis, Infect. Drug Resist., 11, 1645, 10.2147/IDR.S173867 · DOI · Paper page
- Cong, 2020, Vancomycin resistant Staphylococcus aureus infections: A review of case updating and clinical features, J. Adv. Res., 21, 169, 10.1016/j.jare.2019.10.005 · DOI · Paper page
- Robinson, 2003, Evolutionary Models of the Emergence of Methicillin-Resistant Staphylococcus aureus, Antimicrob. Agents Chemother., 47, 3926, 10.1128/AAC.47.12.3926-3934.2003 · DOI · Paper page
- Rolo, J., Worning, P., Boye Nielsen, J., Sobral, R., Bowden, R., Bouchami, O., Damborg, P., Guardabassi, L., Perreten, V., and Westh, H. (2017). Evidence for the evolutionary steps leading to mecA-mediated β-lactam resistance in staphylococci. PLOS Genet., 13. · DOI
- Babakhani, 2018, Transposons: The agents of antibiotic resistance in bacteria, J. Basic Microbiol., 58, 905, 10.1002/jobm.201800204 · DOI · Paper page
- Pillar, 2008, Prevalence of multidrug-resistant, methicillin-resistant Staphylococcus aureus in the United States: Findings of the stratified analysis of the 2004 to 2005 LEADER Surveillance Programs, Diagn. Microbiol. Infect. Dis., 60, 221, 10.1016/j.diagmicrobio.2007.08.007 · DOI
- National Nosocomial Infections Surveillance System (2003). National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992 through June 2003, issued August 2003. Am. J. Infect. Control, 31, 481–498. · DOI · Paper page
- National Nosocomial Infections Surveillance System (2004). National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am. J. Infect. Control, 32, 470–485. · DOI · Paper page
- Ehsanollah, 2009, Anti-adhesive and anti-invasive activities of an oil based di-herbal extract against methicillin resistant Staphylococcus aureus, Afr. J. Microbiol. Res., 3, 272
- Appelbaum, 2004, Vancomycin resistance in Staphylococcus aureus, Clin. Lab. Med., 24, 381, 10.1016/j.cll.2004.03.004 · DOI · Paper page
- Tenover, 2005, Vancomycin-resistant staphylococci and enterococci: Epidemiology and control, Curr. Opin. Infect. Dis., 18, 300, 10.1097/01.qco.0000171923.62699.0c · DOI · Paper page
- Brown, 2005, Guidelines for the laboratory diagnosis and susceptibility testing of methicillin-resistant Staphylococcus aureus (MRSA), J. Antimicrob. Chemother., 56, 1000, 10.1093/jac/dki372 · DOI · Paper page
- Sauvage, 2008, The penicillin-binding proteins: Structure and role in peptidoglycan biosynthesis, FEMS Microbiol. Rev., 32, 234, 10.1111/j.1574-6976.2008.00105.x · DOI · Paper page
- Bauer, 1966, Antibiotic susceptibility testing by a standardized single disc method, Am. J. Clin. Pathol., 45, 149, 10.1093/ajcp/45.4_ts.493 · DOI · Paper page
- Foster, 2017, Antibiotic resistance in Staphylococcus aureus. Current status and future prospects, FEMS Microbiol. Rev., 41, 430, 10.1093/femsre/fux007 · DOI · Paper page
- Jevons, 1961, Celebin-resistant staphylococci, Br Med. J., 1, 124, 10.1136/bmj.1.5219.124-a · DOI · Paper page
- 2015, Staphylococcal Cassette Chromosome mec (SCCmec) in coagulase negative staphylococci, Med. Univ., 17, 229
- Antignac, 2009, Reconstruction of the Phenotypes of Methicillin-Resistant Staphylococcus aureus by Replacement of the Staphylococcal Cassette Chromosome mec with a Plasmid-Borne Copy of Staphylococcus sciuri pbpD Gene, Antimicrob. Agents Chemother., 53, 435, 10.1128/AAC.01099-08 · DOI
- 2003, Methicillin (Oxacillin)-Resistant Staphylococcus aureus Strains Isolated from Major Food Animals and Their Potential Transmission to Humans, Appl. Environ. Microbiol., 69, 6489, 10.1128/AEM.69.11.6489-6494.2003 · DOI · Paper page
- Katzif, 2005, CspA Regulates Pigment Production in Staphylococcus aureus through a SigB-Dependent Mechanism, J. Bacteriol., 187, 8181, 10.1128/JB.187.23.8181-8184.2005 · DOI
- Courvalin, 2009, VanA-Type Vancomycin-Resistant Staphylococcus aureus, Antimicrob. Agents Chemother., 53, 4580, 10.1128/AAC.00346-09 · DOI · Paper page
- Mussa, 2022, Acquired tetracycline resistance genes by transposons and virulence factors in enterococci recovered from overland and aquatic animals: A systematic review, Rev. Aquac., 14, 399, 10.1111/raq.12605 · DOI
- Andersson, 2010, Antibiotic resistance and its cost: Is it possible to reverse resistance?, Nat. Rev. Microbiol., 8, 260, 10.1038/nrmicro2319 · DOI · Paper page
- Monroe, D. (2007). Looking for Chinks in the Armor of Bacterial Biofilms. PLOS Biol., 5. · DOI · Paper page
- Keren, 2004, Persister cells and tolerance to antimicrobials, FEMS Microbiol. Lett., 230, 13, 10.1016/S0378-1097(03)00856-5 · DOI · Paper page
- Hsu, 2005, Dissemination of Multisusceptible Methicillin-Resistant Staphylococcus aureus in Singapore, J. Clin. Microbiol., 43, 2923, 10.1128/JCM.43.6.2923-2925.2005 · DOI
- Mah, 2001, Mechanisms of biofilm resistance to antimicrobial agents, Trends Microbiol., 9, 34, 10.1016/S0966-842X(00)01913-2 · DOI · Paper page
- Stenz, L. (2011). The GTP-Dependant Pleiotropic Repressor” CodY” Regulates Biofilm Formation in Staphylococcus aureus. [Ph.D. Thesis, University of Geneva].
- Lebeaux, 2014, Biofilm-Related Infections: Bridging the Gap between Clinical Management and Fundamental Aspects of Recalcitrance toward Antibiotics, Microbiol. Mol. Biol. Rev., 78, 510, 10.1128/MMBR.00013-14 · DOI · Paper page
- Akturk, E., Oliveira, H., Santos, S.B., Costa, S., Kuyumcu, S., Melo, L.D.R., and Azeredo, J. (2019). Synergistic Action of Phage and Antibiotics: Parameters to Enhance the Killing Efficacy Against Mono and Dual-Species Biofilms. Antibiotics, 8. · DOI · Paper page
- Dickey, J., and Perrot, V. (2019). Adjunct phage treatment enhances the effectiveness of low antibiotic concentration against Staphylococcus aureus biofilms in vitro. PLoS ONE, 14. · doi:10.1371/journal.pone.0209390
- Wang, 2020, Evaluation of Staphylococcal Bacteriophage Sb-1 as an Adjunctive Agent to Antibiotics Against Rifampin-Resistant Staphylococcus aureus Biofilms, Front. Microbiol., 11, 602057, 10.3389/fmicb.2020.602057 · DOI
- Pires, 2022, An overview of the current state of phage therapy for the treatment of biofilm-related infections, Curr. Opin. Virol., 53, 101209, 10.1016/j.coviro.2022.101209 · doi:10.1016/j.coviro.2022.101209
- Atshan, S.S., Hamat, R.A., Coolen, M.J.L., Dykes, G., Sekawi, Z., Mullins, B.J., Than, L.T., Abduljaleel, S.A., and Kicic, A. (2021). The Role of Subinhibitory Concentrations of Daptomycin and Tigecycline in Modulating Virulence in Staphylococcus aureus. Antibiotics, 10. · doi:10.3390/antibiotics10010039
- Chan, 2013, Phage cocktails and the future of phage therapy, Future Microbiol., 8, 769, 10.2217/fmb.13.47 · DOI · Paper page
- Reza, 2014, Dynamics of bacteriophages as a promising antibiofilm agents, J. Pure Appl. Microbiol., 8, 1015
- Miernikiewicz, P., Dąbrowska, K., Piotrowicz, A., Owczarek, B., Wojas-Turek, J., Kicielińska, J., Rossowska, J., Pajtasz-Piasecka, E., Hodyra, K., and Macegoniuk, K. (2013). T4 Phage and Its Head Surface Proteins Do Not Stimulate Inflammatory Mediator Production. PLoS ONE, 8. · DOI
- Letarov, 2017, Adsorption of bacteriophages on bacterial cells, Biochem., 82, 1632
- Twort, 1961, An investigation on the nature of ultra-microscopic viruses, Acta Kravsi, 189, 1241
- 1917, On an invisible microbe antagonistic to dysentery bacilli, CR Acad. Sci., 165, 373
- Abedon, 2011, Phage treatment of human infections, Bacteriophage, 1, 66, 10.4161/bact.1.2.15845 · DOI · Paper page
- Szybalski, 2012, Chapter 3—Clinical Aspects of Phage Therapy, Advances in Virus Research, Volume 83, 73, 10.1016/B978-0-12-394438-2.00003-7 · DOI · Paper page
- Chanishvili, N. (2012). Literature Review of the Practical Application of Bacteriophage Research, Nova Science Publishers, Incorporated.
- Laskin, 2012, Chapter 1—Phage Therapy Pharmacology: Phage Cocktails, Advances in Applied Microbiology, Volume 78, 1, 10.1016/B978-0-12-394805-2.00001-4 · DOI · Paper page
- Levin, 2004, Population and evolutionary dynamics of phage therapy, Nat. Rev. Microbiol., 2, 166, 10.1038/nrmicro822 · DOI · Paper page
- Carvalho, C.M., Gannon, B.W., Halfhide, D.E., Santos, S.B., Hayes, C.M., Roe, J.M., and Azeredo, J. (2010). The in vivo efficacy of two administration routes of a phage cocktail to reduce numbers of Campylobacter coli and Campylobacter jejuni in chickens. BMC Microbiol., 10. · DOI · Paper page
- Merabishvili, M., Pirnay, J.-P., Verbeken, G., Chanishvili, N., Tediashvili, M., Lashkhi, N., Glonti, T., Krylov, V., Mast, J., and Van Parys, L. (2009). Quality-Controlled Small-Scale Production of a Well-Defined Bacteriophage Cocktail for Use in Human Clinical Trials. PLoS ONE, 4. · DOI · Paper page
- Viazis, 2011, Reduction of Escherichia coli O157:H7 viability on hard surfaces by treatment with a bacteriophage mixture, Int. J. Food Microbiol., 145, 37, 10.1016/j.ijfoodmicro.2010.11.021 · doi:10.1016/j.ijfoodmicro.2010.11.021
- Mitchell, 2019, Mini-review: Efficacy of lytic bacteriophages on multispecies biofilms, Biofouling, 35, 472, 10.1080/08927014.2019.1613525 · DOI
- Tian, 2021, Bacteriophage—A Promising Alternative Measure for Bacterial Biofilm Control, Infect. Drug Resist., 14, 205, 10.2147/IDR.S290093 · DOI
- 2016, Bacteriophages as Weapons Against Bacterial Biofilms in the Food Industry, Front. Microbiol., 7, 825
- Sousa, 2014, Pseudomonas aeruginosa Diversification during Infection Development in Cystic Fibrosis Lungs—A Review, Pathogens, 3, 680, 10.3390/pathogens3030680 · DOI · Paper page
- Wright, 2009, A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy, Clin. Otolaryngol., 34, 349, 10.1111/j.1749-4486.2009.01973.x · DOI · Paper page
- Gu, J., Liu, X., Li, Y., Han, W., Lei, L., Yang, Y., Zhao, H., Gao, Y., Song, J., and Lu, R. (2012). A Method for Generation Phage Cocktail with Great Therapeutic Potential. PLoS ONE, 7. · DOI · Paper page
- Chaudhry, W.N., Concepción-Acevedo, J., Park, T., Andleeb, S., Bull, J.J., and Levin, B.R. (2017). Synergy and Order Effects of Antibiotics and Phages in Killing Pseudomonas aeruginosa Biofilms. PLoS ONE, 12. · DOI · Paper page
- Tagliaferri, 2019, Fighting Pathogenic Bacteria on Two Fronts: Phages and Antibiotics as Combined Strategy, Front. Cell. Infect. Microbiol., 9, 22, 10.3389/fcimb.2019.00022 · DOI · Paper page
- Trend, 2018, Use of a Primary Epithelial Cell Screening Tool to Investigate Phage Therapy in Cystic Fibrosis, Front. Pharmacol., 9, 1330, 10.3389/fphar.2018.01330 · DOI
- Estrella, 2016, Characterization of novel Staphylococcus aureus lytic phage and defining their combinatorial virulence using the OmniLog® system, Bacteriophage, 6, e1219440, 10.1080/21597081.2016.1219440 · DOI
- Wunderink, 2012, Linezolid in Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia: A Randomized, Controlled Study, Clin. Infect. Dis., 54, 621, 10.1093/cid/cir895 · DOI · Paper page
- Lee, 2018, Methicillin-resistant Staphylococcus aureus, Nat. Rev. Dis. Prim., 4, 18033, 10.1038/nrdp.2018.33 · DOI · Paper page
- Stewart, 2008, Physiological heterogeneity in biofilms, Nat. Rev. Microbiol., 6, 199, 10.1038/nrmicro1838 · DOI · Paper page
- Garner, 2012, The Relative Contributions of Physical Structure and Cell Density to the Antibiotic Susceptibility of Bacteria in Biofilms, Antimicrob. Agents Chemother., 56, 2967, 10.1128/AAC.06480-11 · DOI · Paper page
- Lehman, S.M., Mearns, G., Rankin, D., Cole, R.A., Smrekar, F., Branston, S.D., and Morales, S. (2019). Design and Preclinical Development of a Phage Product for the Treatment of Antibiotic-Resistant Staphylococcus aureus Infections. Viruses, 11. · DOI
- Chhibber, 2017, Transfersomal Phage Cocktail Is an Effective Treatment against Methicillin-Resistant Staphylococcus aureus-Mediated Skin and Soft Tissue Infections, Antimicrob. Agents Chemother., 61, e02146-16, 10.1128/AAC.02146-16 · DOI
- Prazak, 2019, Bacteriophages Improve Outcomes in Experimental Staphylococcus aureus Ventilator-associated Pneumonia, Am. J. Respir. Crit. Care Med., 200, 1126, 10.1164/rccm.201812-2372OC · doi:10.1164/rccm.201812-2372oc
- Rahman, 2011, Characterization of induced Staphylococcus aureus bacteriophage SAP-26 and its anti-biofilm activity with rifampicin, Biofouling, 27, 1087, 10.1080/08927014.2011.631169 · doi:10.1080/08927014.2011.631169
- Lin, 2017, Phage therapy: An alternative to antibiotics in the age of multi-drug resistance, World J. Gastrointest. Pharmacol. Ther., 8, 162, 10.4292/wjgpt.v8.i3.162 · DOI · Paper page
- Kumaran, 2018, Does Treatment Order Matter? Investigating the Ability of Bacteriophage to Augment Antibiotic Activity against Staphylococcus aureus Biofilms, Front. Microbiol., 9, 127, 10.3389/fmicb.2018.00127 · DOI
- Shimamori, Y., Mitsunaka, S., Yamashita, H., Suzuki, T., Kitao, T., Kubori, T., Nagai, H., Takeda, S., and Ando, H. (2020). Staphylococcal Phage in Combination with Staphylococcus epidermidis as a Potential Treatment for Staphylococcus aureus-Associated Atopic Dermatitis and Suppressor of Phage-Resistant Mutants. Viruses, 13. · DOI
- Brives, 2020, Phage therapy as a potential solution in the fight against AMR: Obstacles and possible futures, Palgrave Commun., 6, 100, 10.1057/s41599-020-0478-4 · DOI · Paper page
- Kortright, 2019, Phage Therapy: A Renewed Approach to Combat Antibiotic-Resistant Bacteria, Cell Host Microbe, 25, 219, 10.1016/j.chom.2019.01.014 · DOI · Paper page
- Aslam, 2019, Novel bacteriophage therapy for treatment of left ventricular assist device infection, J. Heart Lung Transplant., 38, 475, 10.1016/j.healun.2019.01.001 · doi:10.1016/j.healun.2019.01.001
- Doub, J.B., Ng, V.Y., Johnson, A.J., Slomka, M., Fackler, J., Horne, B.A., Brownstein, M.J., Henry, M., Malagon, F., and Biswas, B. (2020). Salvage Bacteriophage Therapy for a Chronic MRSA Prosthetic Joint Infection. Antibiotics, 9. · doi:10.3390/antibiotics9050241
- Gilbey, 2019, Adjunctive bacteriophage therapy for prosthetic valve endocarditis due to Staphylococcus aureus, Med. J. Aust., 211, 142, 10.5694/mja2.50274 · doi:10.5694/mja2.50274
- Ferry, 2020, The Potential Innovative Use of Bacteriophages Within the DAC® Hydrogel to Treat Patients With Knee Megaprosthesis Infection Requiring “Debridement Antibiotics and Implant Retention” and Soft Tissue Coverage as Salvage Therapy, Front. Med., 7, 342, 10.3389/fmed.2020.00342 · DOI
- Ferry, 2020, Phage Therapy as Adjuvant to Conservative Surgery and Antibiotics to Salvage Patients With Relapsing S. aureus Prosthetic Knee Infection, Front. Med., 7, 570572, 10.3389/fmed.2020.570572 · doi:10.3389/fmed.2020.570572
- Rubalskii, E., Ruemke, S., Salmoukas, C., Boyle, E.C., Warnecke, G., Tudorache, I., Shrestha, M., Schmitto, J.D., Martens, A., and Rojas, S.V. (2020). Bacteriophage Therapy for Critical Infections Related to Cardiothoracic Surgery. Antibiotics, 9. · DOI
- Ramirez-Sanchez, C., Gonzales, F., Buckley, M., Biswas, B., Henry, M., Deschenes, M.V., Horne, B.A., Fackler, J., Brownstein, M.J., and Schooley, R.T. (2021). Successful Treatment of Staphylococcus aureus Prosthetic Joint Infection with Bacteriophage Therapy. Viruses, 13. · doi:10.3390/v13061182
- Rojas, S.V., Junghans, S., Fox, H., Lazouski, K., Schramm, R., Morshuis, M., Gummert, J.F., and Gross, J. (2022). Bacteriophage-Enriched Galenic for Intrapericardial Ventricular Assist Device Infection. Antibiotics, 11. · doi:10.3390/antibiotics11050602
- Püschel, A., Skusa, R., Bollensdorf, A., and Gross, J. (2022). Local Treatment of Driveline Infection with Bacteriophages. Antibiotics, 11. · doi:10.3390/antibiotics11101310
- Doub, J.B., Ng, V.Y., Lee, M., Chi, A., Lee, A., Würstle, S., and Chan, B. (2022). Salphage: Salvage Bacteriophage Therapy for Recalcitrant MRSA Prosthetic Joint Infection. Antibiotics, 11. · doi:10.3390/antibiotics11050616
- Schoeffel, J., Wang, E.W., Gill, D., Frackler, J., Horne, B.A., Manson, T., and Doub, J.B. (2022). Successful Use of Salvage Bacteriophage Therapy for a Recalcitrant MRSA Knee and Hip Prosthetic Joint Infection. Pharmaceuticals, 15. · doi:10.3390/ph15020177
- Grambow, 2022, Treatment of an Infected TEVAR with Extra- and Endovascular Bacteriophage Application, EJVES Vasc. Forum, 56, 20, 10.1016/j.ejvsvf.2022.02.004 · doi:10.1016/j.ejvsvf.2022.02.004
- Onsea, J., Soentjens, P., Djebara, S., Merabishvili, M., Depypere, M., Spriet, I., De Munter, P., Debaveye, Y., Nijs, S., and Vanderschot, P. (2019). Bacteriophage Application for Difficult-To-Treat Musculoskeletal Infections: Development of a Standardized Multidisciplinary Treatment Protocol. Viruses, 11. · DOI · Paper page
- Nadareishvili, 2020, Bacteriophage Therapy as a Potential Management Option for Surgical Wound Infections, PHAGE, 1, 158, 10.1089/phage.2020.0010 · DOI
- Van Nieuwenhuyse, B., Galant, C., Brichard, B., Docquier, P.-L., Djebara, S., Pirnay, J.-P., Van der Linden, D., Merabishvili, M., and Chatzis, O. (2021). A Case of In Situ Phage Therapy against Staphylococcus aureus in a Bone Allograft Polymicrobial Biofilm Infection: Outcomes and Phage-Antibiotic Interactions. Viruses, 13. · DOI
- Gupta, 2019, Bacteriophage Therapy of Chronic Nonhealing Wound: Clinical Study, Int. J. Low. Extrem. Wounds, 18, 171, 10.1177/1534734619835115 · DOI
- Rodriguez, 2022, Case Report: Successful use of phage therapy in refractory MRSA chronic rhinosinusitis, Int. J. Infect. Dis., 121, 14, 10.1016/j.ijid.2022.04.049 · doi:10.1016/j.ijid.2022.04.049
- Bleibtreu, 2020, Combining bacteriophages and dalbavancin for salvage therapy of complex Staphylococcus aureus extradural empyema, Médecine Mal. Infect., 50, 458, 10.1016/j.medmal.2020.02.004 · doi:10.1016/j.medmal.2020.02.004
- Johri, 2021, Case Report: Chronic Bacterial Prostatitis Treated With Phage Therapy After Multiple Failed Antibiotic Treatments, Front. Pharmacol., 12, 692614, 10.3389/fphar.2021.692614 · DOI
- Moorthy, 2022, Safety and Pharmacokinetics of Exebacase in an Infant With Disseminated Staphylococcus aureus Infection Clin, Infect. Dis., 75, 338, 10.1093/cid/ciab1015 · doi:10.1093/cid/ciab1015
- Schuch, 2017, Bacteriophage Lysin CF-301, a Potent Antistaphylococcal Biofilm Agent, Antimicrob. Agents Chemother., 61, e02666-16, 10.1128/AAC.02666-16 · DOI · Paper page
- Khullar, 2022, Exploring the therapeutic potential of staphylococcal phage formulations: Current challenges and applications in phage therapy, J. Appl. Microbiol., 132, 3515, 10.1111/jam.15462 · DOI
- Danis-Wlodarczyk, K.M., Wozniak, D.J., and Abedon, S.T. (2021). Treating Bacterial Infections with Bacteriophage-Based Enzybiotics: In Vitro, In Vivo and Clinical Application. Antibiotics, 10. · DOI
- Krylov, 2001, Phagotherapy in terms of bacteriophage genetics: Hopes, perspectives, safety, limitations, Genetika, 37, 869
- Huh, 2019, Bacteriophage interactions with mammalian tissue: Therapeutic applications, Adv. Drug Deliv. Rev., 145, 4, 10.1016/j.addr.2019.01.003 · DOI · Paper page
- Guerin, 2020, Shining Light on Human Gut Bacteriophages, Front. Cell. Infect. Microbiol., 10, 481, 10.3389/fcimb.2020.00481 · DOI
- Barrow, 1997, Bacteriophage therapy and prophylaxis: Rediscovery and renewed assessment of potential, Trends Microbiol., 5, 268, 10.1016/S0966-842X(97)01054-8 · DOI · Paper page
- Park, 2014, Observation of inflammatory responses in mice orally fed with bacteriophage T7, J. Appl. Microbiol., 117, 627, 10.1111/jam.12565 · DOI
- Pirnay, 2011, The Phage Therapy Paradigm: Prêt-à-Porter or Sur-mesure?, Pharm. Res., 28, 934, 10.1007/s11095-010-0313-5 · DOI · Paper page
- Torres-Barceló, C. (2018). Phage Therapy Faces Evolutionary Challenges. Viruses, 10. · DOI
- Kolenda, C., Medina, M., Bonhomme, M., Laumay, F., Roussel-Gaillard, T., Martins-Simoes, P., Tristan, A., Pirot, F., Ferry, T., and Laurent, F. (2022). Phage Therapy against Staphylococcus aureus: Selection and Optimization of Production Protocols of Novel Broad-Spectrum Silviavirus Phages. Pharmaceutics, 14. · DOI
- Sanmukh, S.G., Santos, N.J., Barquilha, C.N., dos Santos, S.A., Duran, B.O., Delella, F.K., Moroz, A., Justulin, L.A., Carvalho, H.F., and Felisbino, S.L. (2021). Exposure to Bacteriophages T4 and M13 Increases Integrin Gene Expression and Impairs Migration of Human PC-3 Prostate Cancer Cells. Antibiotics, 10. · DOI
- Vellon, 2007, Up-regulation of αVβ3 integrin expression is a novel molecular response to chemotherapy-induced cell damage in a heregulin-dependent manner, Differentiation, 75, 819, 10.1111/j.1432-0436.2007.00241.x · DOI
- Bichet, 2021, Bacteriophage uptake by mammalian cell layers represents a potential sink that may impact phage therapy, iScience, 24, 102287, 10.1016/j.isci.2021.102287 · DOI · Paper page
- Hsiao, 2014, Size and cell type dependent uptake of silica nanoparticles, J. Nanomed. Nanotechnol., 5, 1
- Ackermann, 2004, Long-term bacteriophage preservation, WFCC Newsl., 38, 35
- Abdelrahman, F., Easwaran, M., Daramola, O.I., Ragab, S., Lynch, S., Oduselu, T.J., Khan, F.M., Ayobami, A., Adnan, F., and Torrents, E. (2021). Phage-Encoded Endolysins. Antibiotics, 10. · DOI · Paper page
- Szybalski, 2012, Chapter 7—Endolysins as Antimicrobials, Advances in Virus Research, Volume 83, 299, 10.1016/B978-0-12-394438-2.00007-4 · DOI · Paper page
- Brzozowska, 2011, The functions of bacteriophage proteins, Postep. Hig. I Med. Dosw., 65, 167, 10.5604/17322693.936090 · doi:10.5604/17322693.936090
Cited by
Staphylococcus aureus: A Review of the Pathogenesis and Virulence Mechanisms
Touaitia, R., Mairi, A., Ibrahim, N. A., Basher, N. S., Idres, T., & Touati, A. (2025) · Antibiotics · doi:10.3390/antibiotics14050470 · Cited by 273
Metadata
- Authors
- Atshan, S. S., Hamat, R. A., Aljaberi, M. A., Chen, J.-S., Huang, S.-W., Lin, C.-Y., Mullins, B. J., & Kicic, A.
- Venue
- Antibiotics
- Publisher
- MDPI AG
- Published
- 2023-02-01
- Volume
- 12
- Issue
- 2
- Pages
- 286
- ISSN
- 2079-6382
- Cited by
- 36
- References
- 8
- Language
- en
- Funders
- E-Da Hospital (EDAHS111001)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phage Therapy as an Alternative Treatment Modality for Resistant Staphylococcus aureus Infections. https://app.cochat.ai/papers/10.3390/antibiotics12020286
- The paper
- Atshan, S. S., Hamat, R. A., Aljaberi, M. A., Chen, J.-S., Huang, S.-W., Lin, C.-Y., Mullins, B. J., & Kicic, A. (2023). Phage Therapy as an Alternative Treatment Modality for Resistant Staphylococcus aureus Infections. Antibiotics. https://doi.org/10.3390/antibiotics12020286
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.